MARIO BARRO, PhD. Innovation Director, Vaccines. Mario is an Innovation Director, Vaccines at RA Capital. Mario has more than two decades of experience in vaccinology, virology and immunology research in large pharma, government, academy and biotech settings A CV is a list of a person’s scholarly professional work. There is not one standardized way to create your CV, but choosing a specific format for referencing is crucial. View this document to see how to cite publications on a CV or resume For PhD Students When should I use a resume, and when should I use a CV? Think about who will be reading your resume. For academic jobs, you use a CV so that people in your field will appreciate • Worked in team of 10 to organize the Harvard Biotech Club annual Career Fair, attracting 20+ companies and ~ job seekers
Top 10 List Of Alternative Careers For PhD Science Graduates
Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and resume biotech phd on the boards of publicly- and privately-held life science companies.
Peter founded and serves as a Director of No Patient Left Behinda non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Rajeev Shah is a Managing Partner at RA Capital Management. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, resume biotech phd, and research tools, resume biotech phd.
Raj holds a BA from Cornell University, where he majored in Chemistry. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, resume biotech phd spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science.
He is also an active member of the Big Brothers of Massachusetts Bay program. Andrew Levin joined RA Capital Management in and is a Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies.
Beginning inand prior to joining the Investment Manager, he was a Vice President at H. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative.
He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from resume biotech phd Massachusetts Institute of Technology, and an MD from Harvard Medical School. Josh Resnick is a Managing Director resume biotech phd RA Capital Management. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business.
He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital.
Mario is an Innovation Director, Vaccines at RA Capital. Mario has more than two decades of experience in vaccinology, virology and immunology research in large pharma, government, academy and biotech settings.
Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur where he created and executed a novel integrative strategy for influenza vaccine development including Machine Learning, Automation, High Through Put, Antigen Design, Translational Models, Data Viz, Scrum Agile and Resume biotech phd CMC Platforms.
He authored patents in the use of ML to create novel translational models, vaccine antigen selection and design that were tested in the clinic, resume biotech phd.
Prior to this, Mario resume biotech phd a Project Director position at BARDA with the highest US project certification COTR III leading technical completion of multiyear vaccine development programs. He also acted resume biotech phd CSO for a small vaccine start up Global Vaccines Inc that developed novel adjuvants and chimeric viruses for HIV and other targets.
Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics. He earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. He is an active reviewer for NIH grants and contracts. Ryan Berry is an Analyst on the Investment Team at RA Capital Management.
Prior to this role, Ryan was an Associate on the Cardio-Renal Team within the TechAtlas division of RA Capital, where he mapped competitive landscapes of drugs and medical devices for disease indications and capabilities, with a focus on coronary artery disease, stroke, and dyslipidemia.
Ryan holds a BS in Biochemistry and Molecular Cell Biology from the University of Minnesota, Twin Cities, and a PhD in Molecular, resume biotech phd, Cellular and Developmental Biology from Yale University.
His doctoral research focused on cellular mechanisms of adipogenesis. Tess Cameron is a Principal, Strategic Finance at RA Capital Management. Tess comes to RA from Foghorn Therapeutics, where she was Head of Finance. As Engagement Associate at RA Capital Management, Thomas Culman leverages qualitative and quantitative skills to manage a variety of educational, outreach, resume biotech phd, and advocacy-oriented projects.
Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. He worked previously as a Patient Coordinator at Massachusetts General Hospital. Derek DiRocco is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, resume biotech phd, iTeos Therapeutics, Connect Bio, CANbridge, and Werewolf Therapeutics.
Previously, Derek covered solid tumor oncology landscapes. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. Rez Halse is a Partner, RA Ventures at RA Capital Management. Rez brings to RA over 20 years of experience working in the life-science industry.
Prior to RA, he served in a dual role at Merck Research Laboratories MRL, resume biotech phd. He was Vice President of Merck business development and licensing where he led BD activities in the US West CoastEurope, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies.
Rez holds a BSc in biochemistry and PhD in cell biology from Newcastle University, resume biotech phd, UK. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Kira Pharmaceuticals, Research Alliance Corp I, and Research Alliance Corp II.
Matthew holds a BS in Resume biotech phd Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut.
His graduate research investigated innate immune resume biotech phd after intracerebral hemorrhage. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Benjamin previously worked in clinical research as a Site Operations Associate for a contracted research organization specializing in Ophthalmology, resume biotech phd.
Nathaniel is a Principal on the Venture Team at RA Capital Management. Nathaniel graduated from Harvard University with a BA in Molecular and Cellular Biology. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management.
Anurag works on both public and private investments with a focus on Healthcare, Technology, and Services. Prior to this role, Anurag was at Orbimed Advisors where he served as Vice President, Structured Growth Capital and Royalty Opportunities. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones.
Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management.
Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. While at Tamarack, he managed coverage expansion into commercial-stage biotech, resume biotech phd, pharma, and specialty pharma sectors, resume biotech phd.
Prior to Tamarack, Brian held roles as Associate Portfolio Manager and Research Analyst, Healthcare, at Sonar Capital Management. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Dan Marks is a Venture Senior Associate at RA Capital Management. Dan holds resume biotech phd BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences, resume biotech phd.
His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Alex Martinez-Forte is an Analyst, Strategic Finance at RA Capital Management.
Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges.
Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. As Head of Engagement, Jessica Sagers directs a concerted effort at RA Capital Management to analyze, design, and shape internal and external narratives.
She holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University.
Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Zach works on both resume biotech phd and private investments and serves as a Board Director for Adagio Medical, Exo Imaging, LENZ Therapeutics, Nkarta Therapeutics, resume biotech phd, and Sydnexis. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes.
Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. Gerald is the Director of Scientific Operations at RA Capital Management. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School.
His research investigated chromatin structure and transcription factor binding. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Jake Simson is a Partner at RA Capital Management. Jake works on both public and private investments and serves as a Board Director for Xenikos, B, resume biotech phd.
V, Tyra Biosciences, resume biotech phd, AavantiBio, and DiCE Molecules. Previously, Jake covered solid tumor oncology landscapes.
Jake holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University, resume biotech phd. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.
Laura Stoppel is a Principal on the Investment Team at RA Capital Management. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals, resume biotech phd. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders.
Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic resume biotech phd in syndromic autism. Laura Tadvalkar is a Principal on the Venture Team at RA Capital Management. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Prior to RA, Laura was a Principal at MP Healthcare Venture Management.
Prior to MP, She was a Consultant at Clarion Healthcare.
Resumes for PhDs - PhD Career Services - Michigan State University
, time: 14:57RA Capital | Team Page
A CV is a list of a person’s scholarly professional work. There is not one standardized way to create your CV, but choosing a specific format for referencing is crucial. View this document to see how to cite publications on a CV or resume For PhD Students When should I use a resume, and when should I use a CV? Think about who will be reading your resume. For academic jobs, you use a CV so that people in your field will appreciate • Worked in team of 10 to organize the Harvard Biotech Club annual Career Fair, attracting 20+ companies and ~ job seekers Jul 31, · How to Prepare for a Career in the Biotech Industry. Broadbelt says there are five key strategies aspiring professionals can employ to advance their biotechnology careers. 1. Build an educational foundation. Broadbelt says the first key to a successful biotech career is a solid educational foundation rooted in science-related coursework
No comments:
Post a Comment